No connection

Search Results

BFRI vs UNH

BFRI
Biofrontera Inc.
BEARISH
Price
$0.86
Market Cap
$10.0M
Sector
Healthcare
AI Confidence
92%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BFRI
--
UNH
24.43
Forward P/E
BFRI
-3.72
UNH
16.08
P/B Ratio
BFRI
-3.85
UNH
3.11
P/S Ratio
BFRI
0.27
UNH
0.66
EV/EBITDA
BFRI
-0.65
UNH
16.47

Profitability

Gross Margin
BFRI
64.41%
UNH
18.53%
Operating Margin
BFRI
-89.84%
UNH
0.34%
Profit Margin
BFRI
-47.28%
UNH
2.69%
ROE
BFRI
-1191.73%
UNH
12.54%
ROA
BFRI
-64.91%
UNH
3.9%

Growth

Revenue Growth
BFRI
-22.5%
UNH
12.3%
Earnings Growth
BFRI
--
UNH
-99.9%

Financial Health

Debt/Equity
BFRI
--
UNH
0.82
Current Ratio
BFRI
1.15
UNH
0.79
Quick Ratio
BFRI
0.51
UNH
0.7

Dividends

Dividend Yield
BFRI
--
UNH
2.73%
Payout Ratio
BFRI
0.0%
UNH
65.99%

AI Verdict

BFRI BEARISH

BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.

Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

BFRI vs UNH: Head-to-Head Comparison

This page compares Biofrontera Inc. (BFRI) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile